# Creacion Ventures

> Creacion Ventures is a VC fund backing Therapeutics and Biotechnology. See 11 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Boston, United States
- Total investments: 11
- Last investment: Apr 2026
- Lead investor: 9%
- Last updated: Aug 2026

Creacion Ventures is a venture capital firm, focus on investment within the healthcare industry, particularly biopharma space.

## Contacts

5 contacts available for Creacion Ventures. Shizune tracks 1 team members at Creacion Ventures. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/creacion-ventures?utm_source=investor_profile

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Therapeutics | 5 | 45% |
| Biotechnology | 5 | 45% |
| Health Care | 2 | 18% |
| Pharmaceutical | 2 | 18% |
| Life Science | 1 | 9% |

6 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 5 | 45% |
| Series B | 4 | 36% |
| Series C | 1 | 9% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 6 | 55% |
| China | 2 | 18% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Qingsheng Zhu | Founding Partner | 1 | — |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Xinmaide | Xinmaide focuses on the specialized fields of pulmonary drug delivery, nasal drug delivery, and brain drug delivery devices, dedicating its efforts to the research, design, and development of advanced medical technologies that improve how drugs are administered and absorbed in the body. | $43.7M | Series B | Apr 07, 2026 |  |
| Sirius Therapeutics | Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases. | $50M | Series B | May 09, 2025 |  |
| Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $101M | Series C | Dec 05, 2023 |  |
| Sirius Therapeutics | Sirius Therapeutics is an innovative biotechnology company that focuses on RNAi therapies for cardiovascular diseases. | $60M | Series B | Oct 09, 2023 |  |
| QuantX Biosciences | QuantX Biosciences is a biotechnology company that specializes in computational drug discovery and small-molecule therapeutic products. | $45M | Series A | Jan 01, 2023 |  |
| Frontera Therapeutics | Frontera Therapeutics is an AAV gene therapy company with the mission to establish a low-cost and scalable platform, to develop and produce high-quality and affordably priced rAAV therapies for the global market. | $160M | Series B | Jun 24, 2022 |  |
| MOMA Therapeutics | MOMA Therapeutics operates as a biotechnology company. MOMA Therapeutics discover the next generation of precision medicines by targeting the molecular machines that underlie human disease. | $150M | Series B | May 10, 2022 |  |
| Odyssey Therapeutics | Odyssey Therapeutics is a biotechnology company pioneering the efficient development of next-generation immunomodulators and oncology medicines. Odyssey is making a transformational impact on the field of drug discovery and is accelerating the path to clinical development to drive the creation of more effective precision medicines. | $218M | Series A | Dec 07, 2021 |  |
| Parthenon Therapeutics | Parthenon Therapeutics is inventing a novel class of anti-cancer therapies that reprogram the tumor microenvironment (TME). The interplay between cancer cells and their surrounding microenvironment is relevant in drug development as manycancers use the TME to build barriers that shield immune system attack. One approach, PRTH-101, breaks thesebarriers to overcome recalcitrant cancers. Based on research, the company is designing a portfolio of drug candidates to treat the right patients at the right time. | $65M | Series A | Nov 03, 2021 |  |
| Pediatrix Therapeutics | Pediatrix Therapeutics is a pharmaceutical company focused on the field of pediatrics by developing and introducing effective and clinically proven children's medicines to provide Chinese children and families with high-quality and affordable treatment options. |  | Series A | Apr 28, 2021 |  |

10 of 11 investments shown.

## Co-investors
- [OrbiMed](https://shizune.co/investors/profile/orbimed-advisors) — VC Fund, 7 deals together
- [Alexandria Venture Investments](https://shizune.co/investors/profile/alexandria-venture-investments) — VC Fund, 4 deals together
- [Casdin Capital](https://shizune.co/investors/profile/casdin-capital) — VC Fund, 2 deals together
- [Colt Ventures](https://shizune.co/investors/profile/colt-ventures) — VC Fund, 2 deals together
- [Cormorant Asset Management](https://shizune.co/investors/profile/cormorant-asset-management) — VC Fund, 2 deals together
- [Foresite Capital](https://shizune.co/investors/profile/foresite-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Creacion Ventures invest in?

Creacion Ventures invests primarily in Therapeutics, Biotechnology and Health Care startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### How do I contact Creacion Ventures?

For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Creacion Ventures?

The team at Creacion Ventures includes Qingsheng Zhu (Founding Partner). The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co